Literature DB >> 2935624

Atriopeptin III kinetics and pharmacodynamics in normal and anephric rats.

F C Luft, R E Lang, G R Aronoff, H Ruskoaho, M Toth, D Ganten, R B Sterzel, T Unger.   

Abstract

To elucidate the disposition of atriopeptin III in plasma we performed experiments in normal and anephric rats. Bolus, i.v. atriopeptin III (250 ng) was given after which the rats were decapitated at 30-sec intervals. The half-life of atriopeptin III in normal rats was 26.5 sec, the volume of distribution was 352 ml and the plasma clearance was 500 ml/min. In anephric rats the half-life was 56.8 sec, the volume of distribution was 345 ml and the plasma clearance was 206 ml/min. In other rats atriopeptin III was given and urine was collected simultaneously. No atriopeptin III could be measured in the urine. We gave 0.0, 0.067, 0.125, 0.25, 0.5 and 1.0 ng/kg of bolus atriopeptin III to normal rats and measured effects on blood pressure, heart rate and plasma concentration at 30 sec, the time at which maximum effect on blood pressure occurred. Dose, change in blood pressure and plasma concentration were correlated. Heart rate increased, but not in a dose-dependent fashion. We conclude that atriopeptin III is cleared from rat plasma rapidly and that the kidneys account for 59% of its elimination by degradation rather than excretion. Because the effect of atriopeptin III on blood pressure is concentration-dependent, the transient changes exerted by atriopeptin III may be related to its rapid disappearance from plasma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2935624

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

Review 1.  A heart-adipose tissue connection in the regulation of energy metabolism.

Authors:  Sheila Collins
Journal:  Nat Rev Endocrinol       Date:  2013-12-03       Impact factor: 43.330

2.  The behaviorally active peptide ACTH 4-10: measurement in plasma and pharmacokinetics in man.

Authors:  U Bickel; J Born; H L Fehm; M Distler; K H Voigt
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Raised plasma levels of atrial natriuretic factor in cardiac allograft recipients: evidence of increased cardiac secretion and decreased renal clearance.

Authors:  C C Lang; T Moreland; A M Choy; T H Pringle; G P McNeill; A D Struthers
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  Natriuretic and antikaliuretic effects of uroguanylin and prouroguanylin in the rat.

Authors:  Nicholas G Moss; Dorothy A Riguera; Robert C Fellner; Christopher Cazzolla; Michael F Goy
Journal:  Am J Physiol Renal Physiol       Date:  2010-09-22

5.  The action of atriopeptin III on renal function in two models of chronic renal failure in the rat.

Authors:  E J Johns; B Rutkowski
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

6.  Rapid receptor-mediated catabolism of 125I-atrial natriuretic factor by vascular endothelial cells.

Authors:  G R Johnson; L Arik; B J Pitts; C J Foster
Journal:  Biochem J       Date:  1990-06-15       Impact factor: 3.857

7.  Kinetics of atrial natriuretic peptide in young and elderly subjects.

Authors:  A C Tan; T L Jansen; E F Termond; F G Russel; T Thien; P W Kloppenborg; T J Benraad
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 8.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

9.  Atrial natriuretic peptide and cyclic 3'5'-guanosine monophosphate as indicators of fluid volume overload in children with chronic renal failure.

Authors:  B Lettgen; M Bald; H Valleé; K E Bonzel; W Rascher
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

10.  Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan.

Authors:  C Gros; A Souque; J C Schwartz; J Duchier; A Cournot; P Baumer; J M Lecomte
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.